Literature DB >> 19656575

Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies.

Sidney H Kennedy1, Roumen Milev, Peter Giacobbe, Rajamannar Ramasubbu, Raymond W Lam, Sagar V Parikh, Scott B Patten, Arun V Ravindran.   

Abstract

BACKGROUND: In 2001, the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical guidelines for the treatment of depressive disorders. A revision of these guidelines was undertaken by CANMAT in 2008-2009 to reflect advances in the field. There is renewed interest in refined approaches to brain stimulation, particularly for treatment resistant major depressive disorder (MDD).
METHODS: The CANMAT guidelines are based on a question-answer format to enhance accessibility to clinicians. An evidence-based format was used with updated systematic reviews of the literature and recommendations were graded according to Level of Evidence using pre-defined criteria. Lines of Treatment were identified based on criteria that included evidence and expert clinical support. This section on "Neurostimulation Therapies" is one of 5 guidelines articles.
RESULTS: Among the four forms of neurostimulation reviewed in this section, electroconvulsive therapy (ECT) has the most extensive evidence, spanning seven decades. Repetitive transcranial magnetic (rTMS) and vagus nerve stimulation (VNS) have been approved to treat depressed adults in both Canada and the United States with a much smaller evidence base. There is also emerging evidence that deep brain stimulation (DBS) is effective for otherwise treatment resistant depression, but this is an investigational approach in 2009. LIMITATIONS: Compared to other modalities for the treatment of MDD, the data based is limited by the relatively small numbers of randomized controlled trials (RCTs) and small sample sizes.
CONCLUSIONS: There is most evidence to support ECT as a first-line treatment under specific circumstances and rTMS as a second-line treatment. Evidence to support VNS is less robust and DBS remains an investigational treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19656575     DOI: 10.1016/j.jad.2009.06.039

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  35 in total

1.  Treatment-resistant depression in later life.

Authors:  Heba El Bayoumi; Zahinoor Ismail
Journal:  J Psychiatry Neurosci       Date:  2015-11       Impact factor: 6.186

2.  What is the role of brain stimulation therapies in the treatment of depression?

Authors:  Daniel M Blumberger; Benoit H Mulsant; Zafiris J Daskalakis
Journal:  Curr Psychiatry Rep       Date:  2013-07       Impact factor: 5.285

Review 3.  Neuromodulation for treatment-refractory major depressive disorder.

Authors:  Nir Lipsman; Tejas Sankar; Jonathan Downar; Sidney H Kennedy; Andres M Lozano; Peter Giacobbe
Journal:  CMAJ       Date:  2013-07-29       Impact factor: 8.262

4.  Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Adult and Youth Populations: A Systematic Literature Review and Meta-Analysis.

Authors:  Laura E Leggett; Lesley J J Soril; Stephanie Coward; Diane L Lorenzetti; Gail MacKean; Fiona M Clement
Journal:  Prim Care Companion CNS Disord       Date:  2015-11-05

5.  Pharmacological mechanisms of interhemispheric signal propagation: a TMS-EEG study.

Authors:  Jeanette Hui; Reza Zomorrodi; Pantelis Lioumis; Bahar Salavati; Tarek K Rajji; Robert Chen; Daniel M Blumberger; Zafiris J Daskalakis
Journal:  Neuropsychopharmacology       Date:  2019-07-29       Impact factor: 7.853

6.  External Excitation of Neurons Using Electric and Magnetic Fields in One- and Two-dimensional Cultures.

Authors:  Shani Stern; Assaf Rotem; Yuri Burnishev; Eyal Weinreb; Elisha Moses
Journal:  J Vis Exp       Date:  2017-05-07       Impact factor: 1.355

7.  Predicting persistence to antidepressant treatment in administrative claims data: Considering the influence of refill delays and prior persistence on other medications.

Authors:  Greta A Bushnell; Til Stürmer; Alice White; Virginia Pate; Sonja A Swanson; Deborah Azrael; Matthew Miller
Journal:  J Affect Disord       Date:  2016-02-09       Impact factor: 4.839

8.  Alteration of immune markers in a group of melancholic depressed patients and their response to electroconvulsive therapy.

Authors:  Gavin Rush; Aoife O'Donovan; Laura Nagle; Catherine Conway; AnnMaria McCrohan; Cliona O'Farrelly; James V Lucey; Kevin M Malone
Journal:  J Affect Disord       Date:  2016-06-17       Impact factor: 4.839

Review 9.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments.

Authors:  Roumen V Milev; Peter Giacobbe; Sidney H Kennedy; Daniel M Blumberger; Zafiris J Daskalakis; Jonathan Downar; Mandana Modirrousta; Simon Patry; Fidel Vila-Rodriguez; Raymond W Lam; Glenda M MacQueen; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 10.  Challenges in the treatment of major depressive disorder with psychotic features.

Authors:  Anthony J Rothschild
Journal:  Schizophr Bull       Date:  2013-04-18       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.